67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

Authors :: S.L. Chan
M. Kudo
B. Sangro
R.K. Kelley
J. Furuse
J-W. Park
P. Sunpaweravong
A. Fasolo
T. Yau
T. Kawaoka
A-L. Cheng
S. Azevedo
M.E. Reig Monzon
E. Assenat
M. Yarchoan
A.R. He
M. Makowsky
C. Gupta
A. Negro
G.K. Abou-Alfa
Source :: Annals of Oncology. 33:S1456
Publication Year :: 2022
Publisher :: Elsevier BV, 2022.

Tools